All In Biotech

Drug Trial Radar · NCT07877155

To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 2 Clinical Study to Evaluate the Safety and Efficacy of Hemay5394 in Participants With Mild to Moderate Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Nov 3, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Hemay Pharmaceutical PTY. LTD.Industry
Sponsor type
Industry
First posted
Oct 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and efficacy of Hemay5394 in patients with mild to moderate atopic dermatitis

Conditions

  • Safety
  • Efficiency

Interventions

  • Hemay5394 groupDrug

    investigational product,Topical administration, twice daily

  • Control groupDrug

    Compared with the experimental group,Topical administration, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving Eczema Area and Severity Index (EASI)-75Time frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Innovate Clinical Research

    Waitara, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.